Brokerages Set Sotera Health (NASDAQ:SHC) PT at $16.08

Sotera Health (NASDAQ:SHC) has received a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $16.08.

Several research firms have commented on SHC. Citigroup upped their price objective on shares of Sotera Health from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, November 6th. The Goldman Sachs Group assumed coverage on shares of Sotera Health in a research note on Friday, December 6th. They issued a “neutral” rating and a $14.00 price target on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Thursday, November 21st.

Sotera Health Trading Up 0.1 %

Shares of NASDAQ:SHC opened at $13.63 on Friday. Sotera Health has a 52-week low of $10.71 and a 52-week high of $17.44. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. The company has a market capitalization of $3.86 billion, a P/E ratio of 54.52 and a beta of 1.96. The company has a 50-day simple moving average of $13.98 and a 200 day simple moving average of $14.37.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Tuesday, November 5th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The business had revenue of $285.47 million during the quarter, compared to analyst estimates of $278.64 million. Sotera Health had a net margin of 6.31% and a return on equity of 42.27%. The business’s quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.18 earnings per share. Sell-side analysts forecast that Sotera Health will post 0.61 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Darsana Capital Partners LP increased its position in shares of Sotera Health by 716.9% in the third quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company’s stock worth $334,167,000 after purchasing an additional 17,560,636 shares during the period. Sessa Capital IM L.P. grew its stake in Sotera Health by 46.5% during the third quarter. Sessa Capital IM L.P. now owns 6,300,597 shares of the company’s stock worth $105,220,000 after buying an additional 2,000,000 shares in the last quarter. State Street Corp increased its holdings in Sotera Health by 18.5% in the 3rd quarter. State Street Corp now owns 4,126,806 shares of the company’s stock valued at $68,918,000 after buying an additional 644,236 shares during the period. AQR Capital Management LLC raised its position in shares of Sotera Health by 3,198.2% in the 2nd quarter. AQR Capital Management LLC now owns 511,580 shares of the company’s stock valued at $6,072,000 after buying an additional 496,069 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Sotera Health by 19.4% during the 3rd quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company’s stock worth $46,026,000 after acquiring an additional 447,186 shares during the period. 91.03% of the stock is owned by institutional investors.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.